Catherine Parker
Council of Regulators
Health Canada Liaison to the DIA Board
Director General, Biologics & Genetic Therapies Directorate HPFB, Health Canada
Catherine Parker was appointed Director General of the Biologics and Genetic Therapies Directorate (BGTD) of the Health Products and Food Branch, effective 29 June 2015. BGTD is responsible for the regulatory oversight of biologic and radiopharmaceutical drugs for human use in Canada. Ms. Parker was BGTD’s Acting Senior Executive Director from 2013-2014 and previously, was the Director of its Office of Policy and International Collaboration from 2001 to 2012, where she played a key role in the development of several major regulatory initiatives including the Safety of Human Cells, Tissues and Organs for Transplantation Regulations, the new Blood Regulations, and the Global Pandemic Influenza Regulatory Preparedness Initiative. She also held previous positions within BGTD as Director of its Submission Management Division and as a reviewer of biotechnology products. Prior to joining the Health Products and Food Branch, Ms. Parker held the position of biologist within the Laboratory Centre for Disease Control of Health Canada.
Ms. Parker is also Health Canada’s representative at the Assembly and Management Committee of the International Council on Harmonization (ICH) and the Steering Committee of the Pan-American Network for Drug Regulatory Harmonization (PANDRH).
Our Leadership
-
PharmD •Chair DIA
Senior Advisor R&D
Bayer AG -
MBA •Immediate Past Chair DIA
President and Chief Executive Officer
Cancer Genetics, Inc. (CGI) -
RPh •Chair-Elect DIA
Head, Product Development Medical Affairs Customer Strategy
F. Hoffmann-La Roche Ltd. -
CPA, CGMA •Secretary/Treasurer DIA
Chief Financial Officer
Katabat -
MS • Global Chief Executive
DIA
-
MD, PhD, DSc •Director DIA
Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety
Eli Lilly and Company, Ltd. -
MPharm •Director DIA
Executive Director, Global Regulatory Policy
Merck Sharp & Dohme (Europe) Inc. -
MD •Director DIA
Chief Scientific Officer
Syneos Health -
CPA •Director DIA
Partner, Life Science Industry Practice Group, RSM US -
MD •Director DIA
Chief Medical Officer
Flagship Pioneering -
PhD •Director DIA
Senior Vice President
QIAGEN -
MD, PhD •Director DIA
Vice President and Senior Managing Director, Development & Medical Affairs, GlaxoSmithKline Japan -
PhD •Director DIA
Chairman and Chief Executive Officer
dMed Company Limited -
PharmD •Director DIA
President, R&D Design and Delivery Innovation, IQVIA
-
PharmD • Chair, Executive Committee
-
CPA • Member, Executive Committee -
MBA • Member, Executive Committee -
RPh • Member, Executive Committee -
MS • Member, Executive Committee
-
CPA • Chair, Audit Committee -
MD, PhD, DSc • Member, Audit Committee -
MPharm • Member, Audit Committee -
PharmD • Member, Audit Committee -
PharmD • Member, Audit Committee
-
PhD • Chair, Council of Regulators
Leadership Committee
Japan Pharmaceuticals and Medical Devices Agency Liaison to the DIA Board -
PhD • Council of Regulators
Leadership Committee
European Medicines Agency Liaison to the DIA Board -
MD • Council of Regulators
Leadership Committee
US Food and Drug Administration Liaison to the DIA Board -
PhD • Council of Regulators
Swissmedic Liaison to the DIA Board
-
MS • Global Chief Executive -
MS, CPA • Chief Financial Officer -
-
DIA EMEA -
PhD • Senior Vice President & Managing Director
DIA South Korea and ASEAN -
PhD • Senior Vice President & Managing Director
DIA Americas -
PhD • Senior Vice President & Managing Director
DIA Japan -
RPh, MBA • Senior Vice President & Managing Director
DIA Greater China